MoneyShow — an industry pioneer in investor education since 1981 — is a global, financial media company, operating the world's leading investment and trading conferences. Each show brings together thousands of investors to attend workshops, presentations and seminars given by the nation's top financial experts. The company also offers exclusive seminars-at-sea, with the investment industry's leading partners. In addition, MoneyShow operates the award-winning, multimedia online community, Moneyshow.com and p ...

Company Analysis - AbbVie Inc (NYSE: ABBV) shows a 17% upside potential based on DCF model analysis [1] - The company maintains a fundamentally strong business with a diversified portfolio [1] - AbbVie's business is protected by long-term patents, providing stability and competitive advantage [1] Analyst Background - The analyst has 7 years of experience in the US stock market with a focus on portfolio management [1] - The analyst's IT background provides valuable perspective in analyzing technology stocks [1] - The analyst's approach emphasizes fundamental analysis and risk-reward balance in investment decisions [1] Investment Perspective - The analyst holds a beneficial long position in ABBV through stock ownership, options, or derivatives [2] - The analysis represents the analyst's independent opinion without external compensation [2] - The article aims to provide accessible insights for investors across experience levels [1]

NORTH CHICAGO, Ill., Jan. 9, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025. Management will participate in a fireside chat at 10:15 a.m. Central time.A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.About AbbVieAbbVie's mission is to discover and deliver innovative medici ...

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering AbbVie (ABBV) , which belongs to the Zacks Large Cap Pharmaceuticals industry.This drugmaker has an established record of topping earnings estimates, especially when looking at the previous two reports. The company boasts an average surprise for the past two quarters of 2.93%.For the last reported quarter, AbbVie came out with earnings of $3 per share versus ...

Get Treated with CoolSculpting® Elite and Enter for a Chance to Win $10,000* Starting Today, First-Time Users Can Claim $300 Off Their Treatment† IRVINE, Calif., Jan. 7, 2025 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced its third annual CoolMonth featuring CoolSculpting® Elite. The celebration is an opportunity for consumers interested in body contouring to reach out to a CoolSculpting® Elite expert and discuss their body contouring treatment options. CoolSculpting® is the ...

In an SEC filing, AbbVie (ABBV) has disclosed that it is lowering its previously issued guidance for 2024 adjusted earnings per share (EPS) by 88 cents due to in-process research and development (IPR&D) expenses incurred for acquisitions and collaborations during the fourth quarter.The adjusted EPS guidance for full-year 2024 was lowered from $10.90-$10.94 to $10.02-$10.06 due to acquisition costs of $1.6 billion on a pre-tax basis. The Zacks Consensus Estimate for this metric is pegged at $10.96.Including ...

When it comes to dividend investing, there are two basic paths you can take. You could seek out businesses that are raising their payouts at a rapid pace, but these stocks tend to offer low yields. The other basic option available to dividend investors is to buy stocks with really high yields. Unfortunately, stocks rarely offer ultrahigh yields unless there's concern about their ability to raise or maintain their dividend payouts.If you can't decide which dividend investing option you like best, I have some ...

If you're worried about having enough passive income to maintain your lifestyle during retirement, you're not alone. Having to spend more just to maintain their current standard of living is a constant concern for most families.There isn't much that you can do to stop the march of inflation, but you can prepare. Filling your portfolio with dividend-paying stocks that raise their quarterly payouts faster than the underlying inflation rate could even lead to extra spending cash.Medtronic (MDT 0.91%), Bristol ...

NORTH CHICAGO, Ill., Jan. 3, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its full-year and fourth-quarter 2024 financial results on Friday, January 31, 2025, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day. About AbbVie AbbVie's mission is to discover and deliver innovative me ...

Industry Overview - The drug and biotech industry faced challenges in the past months due to disappointing Q3 sales, guidance cuts, and pipeline setbacks, but is expected to recover in 2025 [2] - Innovation in areas like rare diseases, oncology, obesity, immunology, and neuroscience is driving investor interest, with R&D remaining a key focus in 2025 [3] - The Zacks Large Cap Pharmaceuticals industry includes global companies developing drugs for therapeutic areas like neuroscience, cardiovascular, rare diseases, immunology, and oncology, with some also involved in vaccines, animal health, and medical devices [5] - Large drugmakers invest heavily in product pipelines and line extensions, with continuous innovation and M&A activity being defining characteristics [6] Key Drivers and Challenges - Innovation and pipeline success are critical for top-line growth, with pharma companies spending a significant portion of revenues on R&D [7] - Aggressive M&A activity is a key feature, with large companies acquiring smaller biotech firms to build pipelines, particularly in oncology, rare diseases, and cell and gene therapy [8][9] - Recent major M&A deals include Eli Lilly's buyout of Morphic, Vertex's acquisition of Alpine Immune Sciences, and Novo Nordisk's purchase of Catalent [10] - Pipeline setbacks, regulatory delays, pricing pressure, generic competition, and macroeconomic uncertainty are significant headwinds for the industry [11][12] Industry Performance and Valuation - The Zacks Large Cap Pharmaceuticals industry has a Zacks Industry Rank of 146, placing it in the bottom 41% of Zacks industries [14] - The industry has outperformed the Zacks Medical Sector but underperformed the S&P 500, with a 1.2% decline over the past year compared to the S&P 500's 26.2% rise [15] - The industry's forward 12-month P/E ratio is 18.64X, lower than the S&P 500's 25.08X and the Zacks Medical Sector's 25.47X [16] Key Companies to Watch - **J&J**: Diversified business model with strong growth in the Innovative Medicines segment, expected to exceed $57 billion in sales in 2025 [17][18] - **Pfizer**: Strengthened oncology position with Seagen acquisition, expects operational growth driven by new products and cost cuts of at least $5.5 billion [21][22][23] - **AbbVie**: Successfully navigating Humira's loss of exclusivity with new immunology drugs Skyrizi and Rinvoq, expects mid-single-digit revenue growth in 2025 [24][25][26] - **Eli Lilly**: Strong performance from tirzepatide medicines Mounjaro and Zepbound, with demand expected to drive revenue growth in 2025 [28][29][30][31] - **AstraZeneca**: Diversified portfolio with 12 blockbuster drugs, expects industry-leading top-line growth and $80 billion in revenues by 2030 [33][34][35]